Matches in SemOpenAlex for { <https://semopenalex.org/work/W3210090561> ?p ?o ?g. }
- W3210090561 endingPage "1455.e10" @default.
- W3210090561 startingPage "1444" @default.
- W3210090561 abstract "The development of resistance to treatments of melanoma is commonly associated with an upregulation of the MAPK pathway and the development of an undifferentiated state. Previous studies have suggested that melanoma with these resistance characteristics may be susceptible to innate death mechanisms such as pyroptosis triggered by the activation of inflammasomes. In this study, we have taken cell lines from patients before and after the development of resistance to BRAF V600 inhibitors and exposed the resistant melanoma to temozolomide (a commonly used chemotherapy) with and without chloroquine to inhibit autophagy. It was found that melanoma with an inflammatory undifferentiated state appeared susceptible to this combination when tested in vitro and in vivo against xenografts in nonobese diabetic scid gamma mice. Translation of the latter results into patients would promise durable responses in patients treated by the combination. The inflammasome and death mechanism involved appeared to vary between melanoma and involved either AIM2 or NLRP3 inflammasomes and gasdermin D or E. These preliminary studies have raised questions as to the selectivity for different inflammasomes in different melanoma and their selective targeting by chemotherapy. They also question whether the inflammatory state of melanoma may be used as biomarkers to select patients for inflammasome-targeted therapy." @default.
- W3210090561 created "2021-11-08" @default.
- W3210090561 creator A5004239999 @default.
- W3210090561 creator A5014685459 @default.
- W3210090561 creator A5028052339 @default.
- W3210090561 creator A5041063715 @default.
- W3210090561 creator A5045275728 @default.
- W3210090561 creator A5055038393 @default.
- W3210090561 creator A5067942807 @default.
- W3210090561 creator A5069277796 @default.
- W3210090561 creator A5082237249 @default.
- W3210090561 creator A5090852800 @default.
- W3210090561 date "2022-05-01" @default.
- W3210090561 modified "2023-10-01" @default.
- W3210090561 title "Repurposing Melanoma Chemotherapy to Activate Inflammasomes in the Treatment of BRAF/MAPK Inhibitor Resistant Melanoma" @default.
- W3210090561 cites W1516737476 @default.
- W3210090561 cites W1935448348 @default.
- W3210090561 cites W1963774361 @default.
- W3210090561 cites W1990511191 @default.
- W3210090561 cites W2003402062 @default.
- W3210090561 cites W2004516435 @default.
- W3210090561 cites W2017068228 @default.
- W3210090561 cites W2019576484 @default.
- W3210090561 cites W2055510039 @default.
- W3210090561 cites W2064672822 @default.
- W3210090561 cites W2066348726 @default.
- W3210090561 cites W2073363047 @default.
- W3210090561 cites W2088172536 @default.
- W3210090561 cites W2091204948 @default.
- W3210090561 cites W2116978375 @default.
- W3210090561 cites W2136799264 @default.
- W3210090561 cites W2136925048 @default.
- W3210090561 cites W2146862337 @default.
- W3210090561 cites W2158485828 @default.
- W3210090561 cites W2161632339 @default.
- W3210090561 cites W2179438025 @default.
- W3210090561 cites W2197124664 @default.
- W3210090561 cites W2219295994 @default.
- W3210090561 cites W2323326409 @default.
- W3210090561 cites W2513922839 @default.
- W3210090561 cites W2564122215 @default.
- W3210090561 cites W2587048937 @default.
- W3210090561 cites W2605233023 @default.
- W3210090561 cites W2608687752 @default.
- W3210090561 cites W2621895366 @default.
- W3210090561 cites W2752569532 @default.
- W3210090561 cites W2765417948 @default.
- W3210090561 cites W2771090720 @default.
- W3210090561 cites W2791483720 @default.
- W3210090561 cites W2797906965 @default.
- W3210090561 cites W2810243923 @default.
- W3210090561 cites W2888057265 @default.
- W3210090561 cites W2901516234 @default.
- W3210090561 cites W2911937431 @default.
- W3210090561 cites W2912456393 @default.
- W3210090561 cites W2918680959 @default.
- W3210090561 cites W2923527365 @default.
- W3210090561 cites W2936083981 @default.
- W3210090561 cites W2936119023 @default.
- W3210090561 cites W2946033719 @default.
- W3210090561 cites W2950939271 @default.
- W3210090561 cites W2965531670 @default.
- W3210090561 cites W2969538494 @default.
- W3210090561 cites W2976533954 @default.
- W3210090561 cites W2983652778 @default.
- W3210090561 cites W2988723703 @default.
- W3210090561 cites W2993434511 @default.
- W3210090561 cites W3004759823 @default.
- W3210090561 cites W3005273346 @default.
- W3210090561 cites W3005546631 @default.
- W3210090561 cites W3011500848 @default.
- W3210090561 cites W3014572587 @default.
- W3210090561 cites W3016811071 @default.
- W3210090561 cites W3022981886 @default.
- W3210090561 cites W3024912347 @default.
- W3210090561 cites W3040807962 @default.
- W3210090561 cites W3084494759 @default.
- W3210090561 cites W3139294209 @default.
- W3210090561 cites W3159504492 @default.
- W3210090561 cites W3175958373 @default.
- W3210090561 cites W3195032526 @default.
- W3210090561 doi "https://doi.org/10.1016/j.jid.2021.09.030" @default.
- W3210090561 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34695412" @default.
- W3210090561 hasPublicationYear "2022" @default.
- W3210090561 type Work @default.
- W3210090561 sameAs 3210090561 @default.
- W3210090561 citedByCount "9" @default.
- W3210090561 countsByYear W32100905612021 @default.
- W3210090561 countsByYear W32100905612022 @default.
- W3210090561 countsByYear W32100905612023 @default.
- W3210090561 crossrefType "journal-article" @default.
- W3210090561 hasAuthorship W3210090561A5004239999 @default.
- W3210090561 hasAuthorship W3210090561A5014685459 @default.
- W3210090561 hasAuthorship W3210090561A5028052339 @default.
- W3210090561 hasAuthorship W3210090561A5041063715 @default.
- W3210090561 hasAuthorship W3210090561A5045275728 @default.
- W3210090561 hasAuthorship W3210090561A5055038393 @default.
- W3210090561 hasAuthorship W3210090561A5067942807 @default.